- Home
- BUJA vs MRNS Comparison
BUJA vs MRNS Comparison
Compare BUJA & MRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BUJA
- MRNS
- Stock Information
- Founded
- BUJA 2022
- MRNS 2003
- Country
- BUJA Malaysia
- MRNS United States
- Employees
- BUJA N/A
- MRNS N/A
- Industry
- BUJA Blank Checks
- MRNS Biotechnology: Pharmaceutical Preparations
- Sector
- BUJA Finance
- MRNS Health Care
- Exchange
- BUJA Nasdaq
- MRNS Nasdaq
- Market Cap
- BUJA N/A
- MRNS 104.7M
- IPO Year
- BUJA 2023
- MRNS 2014
- Fundamental
- Price
- BUJA $10.96
- MRNS $0.31
- Analyst Decision
- BUJA
- MRNS Buy
- Analyst Count
- BUJA 0
- MRNS 12
- Target Price
- BUJA N/A
- MRNS $4.56
- AVG Volume (30 Days)
- BUJA 2.7K
- MRNS 5.7M
- Earning Date
- BUJA 01-01-0001
- MRNS 11-05-2024
- Dividend Yield
- BUJA N/A
- MRNS N/A
- EPS Growth
- BUJA N/A
- MRNS N/A
- EPS
- BUJA 0.29
- MRNS N/A
- Revenue
- BUJA N/A
- MRNS $30,263,000.00
- Revenue This Year
- BUJA N/A
- MRNS $21.18
- Revenue Next Year
- BUJA N/A
- MRNS $56.42
- P/E Ratio
- BUJA $37.13
- MRNS N/A
- Revenue Growth
- BUJA N/A
- MRNS 16.56
- 52 Week Low
- BUJA $10.30
- MRNS $0.26
- 52 Week High
- BUJA $12.18
- MRNS $11.26
- Technical
- Relative Strength Index (RSI)
- BUJA 67.66
- MRNS 21.75
- Support Level
- BUJA $10.85
- MRNS $0.29
- Resistance Level
- BUJA $10.85
- MRNS $1.96
- Average True Range (ATR)
- BUJA 0.00
- MRNS 0.12
- MACD
- BUJA -0.00
- MRNS -0.18
- Stochastic Oscillator
- BUJA 87.50
- MRNS 2.41
About BUJA Bukit Jalil Global Acquisition 1 Ltd.
Bukit Jalil Global Acquisition 1 Ltd is a blank check company.
About MRNS Marinus Pharmaceuticals Inc.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.